Skin tumors can arise as a result of cumulative genetic abnormalities including chromosomal aberrations that can be described as either morphological (structural rearrangements) or molecular (copy number variations). Cytogenetic techniques have been used to examine both large and small chromosomal aberrations, and include karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization.
Introduction
Since the late 1950's, cytogenetic techniques have been employed to investigate chromosomal aberrations contributing to human disease, including those associated with solid and hematological tumors (1) . Historically, it has been considered the gold standard for prenatal diagnosis of chromosomal abnormalities, as well as for the diagnosis and prognostication of a number of human cancers, including chronic myeloid leukemia (CML) (2) , myelodysplastic syndrome (3) and Ewing sarcoma (4) . Cytogenetic analyses of pre-malignant and malignant skin lesions have identified a number of aberrant regions that appear to contribute to disease development and progression.
Technologies
Some of the earliest cytogenetic studies investigated large chromosomal rearrangements that were easily detectable by microscopy using chromosomal banding patterns (i.e.; G-banding). The identification of the Philadelphia chromosome in 1960 (5) , later defined as a translocation between chromosomes 9 and 22 [t(9;22)] (6), was the first chromosomal abnormality found to be consistently associated with a specific malignancy (CML). Since then, many translocations, duplications and inversions have been identified in various malignancies utilizing banding techniques. While karyotypic testing of hematological malignancies is extremely successful in determining chromosomal abnormalities, the analysis of solid tumors has been much more problematic, due to the necessity for short-or long-term cell culture in the latter, including skin tumors.
Specifically, growth of melanoma and non-melanoma skin cancer (NMSC) cell cultures have identified preferential growth of contaminating stromal fibroblasts in NMSC (7) and subclone selection in melanoma (8) . Caution is therefore warranted when interpreting cytogenetic abnormalities detected in samples derived from cultured skin tumors.
Comparative genomic hybridization (CGH) is a fluorescent-based technique that
alleviates some of the problems associated with cell culturing, as DNA derived directly from a tumor sample can be used as a template to globally screen for gross (>20mb) copy number aberrations (9) . Whole-genome amplified and differentially labeled tumor and reference DNA are co-hybridized to normal metaphase spreads, such that imbalances are detected by changes in fluorescence values of the tumor DNA relative to the reference DNA (9, 10) . The main drawback of CGH analysis is that it detects only relatively large numerical or unbalanced alterations. However it does not require the interpretation of complex tumor karyotypes or prior knowledge of aberrations for probe design, and can therefore easily detect previously unknown DNA copy number variation (CNV) (9, 10) .
Fluorescence in situ hybridization (FISH), detects copy number changes, translocations and inversions that might otherwise be difficult to detect using standard karyotypic analysis (10) (11) (12) . The resolution of FISH is much higher than that of CGH (10) (11) (12) . FISH is applicable to both interphase and metaphase chromosomal analysis, but requires the design of sequence-specific probes that can be large (up to a whole chromosome) or small (as low as 1-200kb) , and therefore prior knowledge of the aberrant region is required (10) (11) (12) .
Loss of heterozygosity (LOH) analysis, although not a cytogenetic technique per se, is often used to confirm and better resolve regions associated with loss of genetic material detected by other methodologies. Highly polymorphic markers or specific genes are used to determine the presence of genetic material in both normal and tumor DNA from an individual, with allelic loss in the tumor tissue correlating with a deleted chromosomal region (13) .
More recently, detection of copy number and structural aberrations has reached a new standard with the introduction of array-CGH (14) , CNV-microarrays (15) and whole-genome sequencing (16) . In conjunction with other molecular techniques (outlined in Chapter 3), cytogenetic analysis is a powerful means to identify genetic factors that drive tumorigenesis and has been employed in the study of skin tumors. The determination of numerical and/or structural chromosomal aberrations, accompanied by further refinement of these regions, will facilitate the identification of putative oncogenes and tumor suppressor genes associated with cancer development and progression.
In addition, a number of online databases exist that summarize cytogenetic aberrations in human cancers [for a review see (17) ], including the Mitelman Database of Chromosome Aberrations in Cancer (18) and the Atlas of Genetics and Cytogenetics in Oncology and Hematology (19) .
Primary Skin Cancers
Cancer of the skin describes the uncontrolled growth of cutaneous cells, arising from an accumulation of inherited and/or sporadic genetic abnormalities, and with the potential for metastatic spread to other organ systems. Classified into two broad categories, melanoma and NMSC, skin cancers are some of the most common human tumors in 5 many countries and their incidence is rapidly increasing. NMSC include basal cell carcinoma (BCC), squamous cell carcinoma (SCC), actinic keratosis (AK), SCC in situ, and keratoacanthoma (KA) (20) . Other primary skin cancers include merkel cell carcinoma (MCC), dermatofibrosarcoma protuberans (DFSP) and cutaneous lymphomas (20, 21) . Extensive cytogenetic analysis of many of these tumors has been conducted and reveals a number of recurrent aberrations that are likely to be associated with the development or progression of skin cancer.
Melanocytic Skin Tumors
Cutaneous melanoma is the most deadly form of skin cancer (22) . In the United States, it is estimated that, in 2009, 68,720 individuals will be diagnosed with melanoma (~22.6 per 100,000 individuals) and that 8,650 individuals will die from this disease (~2.8 per 100,000 individuals) (22) .
Summarized information from the Atlas of Genetics and Cytogenetics in
Oncology and Hematology indicates that the most common karyotypic aberrations associated with melanoma are deletions and translocations involving chromosomes 1 and 6q; gain of 6p, which may play a role in cancer progression; and gain of chromosome 7, which is associated with late stages of the disease (19) . Höglund et al. (23) authored a comprehensive review of genetic changes in melanoma using previously published data obtained from the Mitelman Database of Chromosome Aberrations in Cancer (18) . They noted that most common aberrations detected were -10 (59%), -6q10-q27 (42%), -9p10-p24, -21 (37%), +7, -16 (36%), -14, +1q24-q44, -4, -15 (33%), -5 (32%), -1p10-p36, -11q23-q25 (28%), -12q13-q24, +20 (27%), -17p, +18 (26%), -8p10-p23, 6 +8q10-q24 (25%), -3 (24%), -22, -X (23%), +6p21-p25, -18 (22%), +3 (18%), -19 (17%), +9q22-q34 (15%), +19 (14%), +13, +17q10-q25 (12%), +2, +15, +21 and +22 (11%) (23) . CGH analysis has also identified a number of chromosomal regions with recurrent aberrations in melanoma. Bastian et al. (24) studied 132 melanomas and identified recurrent gain of 6p (37%), 1q (33%), 7p, 7q (32%), 8q (25%), 17q (24%) and 20q (22%), and recurrent loss of 9p (64%), 9q, 10q (36%), 10p (30%), 6q (26%) and 11q (21%).
Genomic imbalance in melanoma is common, with chromosomal gain and loss being reported on all chromosomes (18) . In addition to these aberrations, which result in an imbalance of genetic material, balanced translocations involving regions on 1q, 6q, 14q and 19p have also been identified, although in a smaller percentage of cases (18) . (24) . This aberration was not found in any of the melanomas studied (24) . Early chromosomal instability detected in BMN could define lesions that have a higher potential for oncogenic transformation; although specific chromosomal aberrations may not 7 necessarily be consistent during such transformation. Recurrent alterations, predominantly deletions, have been identified on chromosome 9 in both dysplastic melanocytic nevi and metastatic melanoma lesions (19, 27) , suggesting that this may be a primary event in melanocytic transformation. Höglund et al. (23) suggested two major karyotypic pathways as early cytogenetic changes in melanoma: (i) one involving +6p, -6q and possibly -16 and (ii) a second involving -3 and either +8q or -8p. A CGH study investigating 16 primary melanomas and 12 metastatic tumors identified gains of 5p, 5q21-q23, 10p and 18q, as well as losses of 2p21-pter, 11q13-q23, 12q24.1-qter, 19q13.1-qter and 22qter in metastatic lesions but not in primary lesions (28) . Also, losses involving 9p and 17 occurred at a higher frequency in metastatic tumors (28) . In cases where the primary and metastatic lesions (n=4) were excised from the same patient, metastases were associated with the acquisition of additional aberrations; although none of these were determined to be recurrent (28) . in nodular (61%) and superficial spreading (27%) melanomas (30); (iii) copy number gains of 7 (40.9%), 6, 17 (27%), 9 and 10 (23%) and monosomies of 10 (55%), 9 (37%), 6 (27%), 17 (23%), 1 and 7 (18%) (31); and (iv) polysomy of chromosome 7 (67%) that is associated with amplification of EGFR (epidermal growth factor receptor), as well as common alterations of +6, +8, -9 and -10 (32). A higher frequency of LOH on 1p and 9p is found in melanoma (29% and 50% at the most frequently lost loci) compared to 8 dysplastic nevi (12% and 27% at corresponding loci) and BMN (no LOH) (33). Uribe et al. (34) found loss of 9p21, 17q21, 6q23, and 5q35 more frequently in melanoma (68%), compared to atypical nevi (57%) and BMN (27%). In another study of 13 cases of early-stage melanoma, LOH was detected for at least one locus at 9p22 (31%), 10q11 (31%) and 1p36 (15%) (35) . Udart et al. (36) determined that metastatic melanomas have higher rates of +7 (25%) compared to primary lesions (8%). However, a higher prevalence of additional copies of CCND1 (11q13) is found in primary (47%) versus metastatic (35%) lesions (37) . Although there is not a clear model to describe the influence of CNV on the development and progression of melanoma, studies to date suggest that a number of chromosomal regions may play a role in the early formation of cancerous cells (9p) as well as a metastatic phenotype (7, 11q ). 
Keratinocytic Skin Tumors
The American Cancer Society estimates that more than one million cases of NMSC arise each year (~300 cases per 100,000 individuals) (39) . BCC accounts for ~80% of skin cancer with a lifetime risk of about 28-30% (40) . BCC is locally invasive and destructive, but has a low metastatic potential of 0.0028-0.55% (41) . SCC accounts for ~20% of skin cancers with a lifetime risk of 7-11% (42, 43) . Compared with BCC, it has a much higher and more variable metastatic potential of 3.6%-30%, depending on the site and etiology of the lesion (44) . It has been suggested that all SCC are derived from precursor lesions (i.e.; AK); although only 0.1-10% of AK lesions are known to progress to SCC (45) (46) (47) .
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AK has a prevalence ranging from 11% to as high as 80% in different populations and age groups (45, 48) . SCC in situ progresses to invasive SCC in only a small number of cases (2-5%) and demonstrates a low metastatic potential (49,50). The incidence of SCC in situ can vary from 14.9 to 142 per 100,000 individuals, depending on the ethnic population studied (51) . Keratoacanthoma (KA) has been classified as either a distinct lesion or a subtype of SCC, and its reported incidence varies from 7 to 104 per 100,000 (52) . KA lesions are commonly solitary, demonstrate phases of growth, maturation and spontaneous regression, and rarely metastasize (44) . Given the differing metastatic capabilities of NMSC lesions, the degree of chromosomal instability between each of the lesions would also expected to vary. (57) . CGH analysis of 15 BCC samples identified recurrent CNV, such as gain of 6p (47%), 6q, 9p (20%), 7 and X (13%), as well as loss of 9q (33%) (58) . Follow-up LOH analysis determined loss of 9q22.3 in 53% of cases (58) . Other studies have found LOH at 9q22 (46-60%), 9p21-p22 (55%), 17q21 (34%), 1q (14%), and 17p13 (11%) in BCC (59) (60) (61) (62) (27%), 10p, X (23%) and 9p (18%) (63) . Isochromosomes (defined as a chromosome that has lost one of its arms and replaced it with an exact copy of the other arm) such as i(1p), i(1q), i(5p), i(8q), i(9p), and i(9q) (all <20%), were also represented in these cases, with i(8q) and i(9q) believed to be early genetic events (63) . By examining direct preparations of three primary cutaneous SCC, Casalone et al. (57) identified aberrations not detected in short-term cultures, including -1, +6, +8, +9, +11, -14, +16 and +21; although due to a limited number of samples, these could not be considered recurrent. Using CGH, gains of 3q (47%), 17q (40%), 14q, Xq (33%), 4p, 8q (27%), 1q, 5p, 7q, 9q, 10q and 20q (20%), and losses of 3p (53%), 18q (47%), 17p (33%), 4q (27%), 5q, 8p, 11p, 13q and 18p (20%) were identified in a study of 14 SCC, including five arising from an adjacent AK (64) . Although many of the CNVs were shared between SCC and AK, loss of 18q was specific to SCC (P value = 0.04) and may indicate an important region relating to malignant progression (64) . Another study investigated five SCC cell lines and identified recurrent gains on 11q (100%), 7p (60%) and 8q (60%), and recurrent losses on 3 (80%), 9p (80%) and 8p (60%) (65) . LOH analysis of SCC (including in situ lesions) has revealed frequent loss of 17q (43%), 13q (38%), 17p (34%), 9p (32%), 3p (26%) and 2q (20%) (59) . Recurrent aberrations associated with SCC (>10%), as detected by karyotypic, CGH and LOH analysis can be seen in Figure 4 and -22 (33%) (78). CGH analysis has identified recurrent numerical aberrations, including +19q (63%), +19p (50%), +1p (54%), -3p (46%), +1q, +X (42%), +5p, +8q (38%), -10, +3q, -13q (33%), +20p (29%), +7p, -17p, +20q (25%), -5q, +6q, +7q, -8p, +13q, +18q (21%), -11q and +21 (17%) in MCC (77) . In addition, the average number of imbalances was noted to be different in patients surviving >24 months (6.6) compared with <24 months (11.2) (77). In another study, CGH analysis of 19 cases revealed many of the same recurrent aberrations, including +6 (42%), +1q11-q31, +5p (32%), +1q32-qter (26%), +1p33-pter, +12, -13q13-q31 (21%) and -4q (16%) (89) . FISH analysis of 10 cutaneous MCC lesions has also confirmed +6 in 60% of cases (80) Cutaneous lymphomas, including cutaneous T-cell lymphoma (CTCL) and cutaneous B-cell lymphoma (CBCL) subtypes, affect approximately 3 in 1,000,000 people annually (21) . CTCL is the more common of the two subtypes, affecting about 1,500 individuals annually (89) , and includes mycosis fungoides (MF) and Sezary syndrome (SS) (90) . CBCL accounts for only 10-25% of cutaneous lymphomas (21) and includes follicular lymphoma (FL), marginal zone B-cell lymphoma and large B-cell lymphoma subtypes (91) . Karyotypic testing of 18 SS lesions revealed structural aberrations of chromosomes 10, 17 (28%), 1p (22%), 6q, and 14q (17%) (92) . FISH analysis verified rearrangements of 1p, 17p (33%), and 10 (27%) (92) . CGH analysis of MF lesions has revealed recurrent numerical aberrations of 1p (38%), -17p (21%), +4/4q (18%), -10q/10, +18, -19 (15%), and +17q/17 (12%) (92) . A review of 166 SS samples 14 revealed recurrent losses of chromosomes 1, 2, 6q, 9, 10, 13, 16 and 17, as well as structural rearrangement of 17q (93) . In another study, CGH analysis of three MF and four SS cases identified recurrent copy number changes of -10q23 (29%) and +17q11.2 (71%), suggesting that the duplication at 17q seen in both MF and SS may be an early clonal event (94) . LOH analysis has detected recurrent deletions at 9p (46%), 17p (42%), 10q and 2p (14%) in 15 cases of SS, and at 9p (16%), 10q (12%), 1p and 17p (10%) in 51 cases of MF (90) . Translocations involving MYC and BCL6, independent of the IGH locus, were detected in an additional 7% and 21% of lesions, respectively (97) .
Recent Advances in Cytogenetic Detection Methods
While cytogenetic methods have predominantly been employed as research tools for the genetic characterization of diseases, recent advances in these technologies has prompted 15 interest in their use in the diagnostic setting. However, their routine clinical implementation has been hampered by high cost, prolonged turnaround time, and the expertise required for most cytogenetic detection methods. Nonetheless, efforts have been undertaken to increase their application by reducing time and cost, and increasing the convenience and automation of these methods.
Array-based CGH (aCGH) utilizes microarray chips dotted with thousands of positionally-defined specific probes, to which differentially labeled normal and tumor DNA are co-hybridized, and scanned using computerized fluorescence imaging and analysis systems (14) . This has allowed CGH resolution to vastly improve, from >5-20 mb (for traditional CGH) to <100 kbp, with some high-resolution tiling arrays (HR-CGH) now able to resolve to 50-200 bp (98) . In addition, single nucleotide polymorphism (SNP)-based CNV arrays can detect microscopic CNVs, polyploidy, mosaicisms and uniparental disomy (99, 100) . A number of studies using aCGH and CNV-arrays have been performed on skin cancers. These techniques have confirmed and better resolved many of the genomic aberrations seen in previous traditional CGH and LOH studies, as well as identifying novel alterations. Next-generation sequencing has recently been implemented as a cytogenetic tool, in an effort to more easily detect structural abnormalities, such as translocations and inversions (16) . However, as a result of current costs, it has not yet been used widely and no studies to date have utilized this methodology to detect genomic aberrations in skin cancers.
aCGH analysis of five cell lines derived from different melanoma metastases in a single patient identified a primary cluster of genomic imbalances, including +3p, +7, -9p, -10p, -14q, -16q, -17p and +17q (101). Another study, investigating two formalin-fixed paraffin-embedded (FFPE) melanoma samples, confirmed known aberrations of +1q and -9p (102) . More recently, two large aCGH studies of melanoma samples (126 and 102 samples; 80 shared cases) were undertaken (103, 104) . In these reports, Curtin et al. (29%) and BCC (17%) using aCGH. In an effort to support the applicability of aCGH in the clinical setting, a study on archival FFPE SCC, SCC precursors and normal skin has also been undertaken (106) . The most common aberration detected was loss of 10q-ter, containing the INPP5A (10q26.3) tumor suppressor gene, which was found in both SCC in situ and SCC, but not in non-tumorous sun-damaged skin (106) . CNV-array analysis of 16 primary SCC and 2 metastatic SCC identified common LOH at 2q, 3p, 8p, 9p and 13, as well as gains at 3q and 8q (107) . Analysis of paired primary and metastatic SCC (to lymph nodes) from two of these patients suggested that the primary and metastatic lesions shared common genetic aberrations (although these were different for the two patients), and that the acquisition of additional genetic aberrations is associated with metastatic spread in SCC (107) . LOH at 9q21-q31 was detected in ~93% of BCC (108), suggesting a much higher rate of 9q loss than previously detected with other techniques (58) (59) (60) (61) . In addition, loss of a novel region, 6q23-q27, was identified in 36% of BCC (108) . These studies support CNV-arrays as a powerful tool for the identification of novel cytogenetic aberrations. aCGH has also been used to investigate MCC, DFSP and MF lesions. In a study of 25 MCC samples, oligonucleotide aCGH was used to detect recurrent aberrations of +1, -3p, +3q, -4, +5p, -5q, +6, -7, -10 and -13 (109) . In addition, increasing numbers of genomic aberrations correlated with decreased patient survival (p = 0.04) (109) . Another aCGH study of 10 cases of MCC detected recurrent aberrations, including +1q, +6p, +11
and -17p (110) . In the case of DFSP, aCGH analysis using a pooled approach identified recurrent copy number gains of +8q24.3, +17q21.33-qter and +22cen-q13.1 (84) . 
Implications of Cytogenetic Findings
The employment of cytogenetic methods, in concert with other molecular techniques (outlined in Chapter 3), has greatly increased our ability to identify putative genes or genetic regions associated with tumorigenesis. Genomic aberrations associated with skin tumors include those that are shared amongst a number of different lesions and those that are distinct to a particular lesion or even present at a specific stage of skin cancer development. In addition, the degree of genomic instability appears to be a measure of It is also evident that amplifications and deletions in some regions are detected at similar frequencies within the same types of skin lesions, including chromosomes 9q, 15, 18, 19, 21 and 22 in melanoma and 4q and 9q in AK. Some of these changes may reflect background genomic instability rather than being directly associated with tumorigenesis.
Additionally, it has also been shown that regions of amplification contain genes that are both over-and under-expressed, indicating that chromosomal aberrations do not always reflect changes at the genetic level (127) .
Some aberrations are found to be more prominent in specific skin cancers. For 20 example, loss of 18q in SCC as compared to AK. 18q harbors potential candidate genes SMAD2 (18q21) and SMAD4 (18q21.1) that mediate TGF-beta signaling and cell growth regulation (128) , and which have been implicated in malignant progression in other non-cutaneous tumors (129, 130) . Another example is loss of 9q22 in sporadic BCC. 9q22 contains the PTCH1 (9q22.3) tumor suppressor gene that is part of the hedgehog developmental signaling pathway, which has been implicated in the pathogenesis of hereditary BCC (131) . In DFSP, translocation involving 17q22 and 22q13 creates a gene fusion between COL1A1 (17q21.31-q22) and PDGFB (22q12.3-13.1), resulting in aberrant expression of PDGFB (84) which promotes cellular proliferation, disorganized growth and inhibits apoptosis (132, 133) . Other studies have implicated aberrations in specific regions as early events in skin tumor development, such as loss of 9p (CDKN2A locus), which has been detected in dysplastic nevi, primary and metastatic melanoma (19, 27, 28, (33) (34) (35) , as well as in SCC and AK (69) .
Cytogenetic analysis is a powerful means to detect aberrant chromosomal regions that may harbor tumor suppressor genes and oncogenes. Analyses of melanoma and NMSC have identified a number of consistently aberrant regions. These regions contain genes, which when altered have been implicated in cancer pathogenesis and progression pathways, including cell growth, signaling, differentiation and apoptosis. In addition, some aberrant regions appear to be specific to only one type of skin tumor, possibly containing genes more relevant to the morphological characteristics and/or biologic behavior of that particular skin tumor. The implementation of newer cytogenetic techniques with higher resolutions of detection will continue to improve our understanding of the genetic basis of skin tumors. 
